Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather Ribaudo

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
AIDS (London, England)|September 16, 2024
Proteinuria and albuminuria among a global primary cardiovascular disease prevention cohort of people with HIVEdgar T Overton, Amy Kantor, Kathleen V Fitch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 17, 2024
Brief Report: Low-Dose Methotrexate Does Not Affect Measures of HIV-1 Persistence in Individuals With Chronically Treated HIV-1 InfectionJoshua C Cyktor, Eunice Yeh, Heather Ribaudo, et al.
The Journal of Infectious Diseases|May 10, 2022
Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic SubstudyMárton Kolossváry, Chris deFilippi, Michael T Lu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 12, 2022
Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIVEdgar T Overton, Isabelle R Weir, Markella V Zanni, et al.
Journal of the American Heart Association|December 11, 2025
Baseline ECG and Cardiovascular Outcomes in People With HIV: Insights From REPRIEVEAya Awwad, Christopher de Filippi, Heather Ribaudo, et al.
AIDS (London, England)|May 27, 2025
Risks for sudden cardiac and undetermined cause of death among people with HIV in the REPRIEVE primary cardiovascular prevention trialChristopher deFilippi, Aya Awwad, Gerald S Bloomfield, et al.
JAMA Network Open|June 29, 2021
Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular PreventionUdo Hoffmann, Michael T Lu, Borek Foldyna, et al.
American Heart Journal|April 1, 2019
Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkersUdo Hoffmann, Michael T Lu, Devvora Olalere, et al.
JACC. Advances|June 28, 2024
Coronary Plaque in People With HIV vs Non-HIV Asymptomatic Community and Symptomatic Higher-Risk PopulationsJulia Karady, Michael T Lu, Göran Bergström, et al.
JAMA Cardiology|February 21, 2024
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical TrialMichael T Lu, Heather Ribaudo, Borek Foldyna, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
AIDS (London, England)|September 16, 2024
Proteinuria and albuminuria among a global primary cardiovascular disease prevention cohort of people with HIVEdgar T Overton, Amy Kantor, Kathleen V Fitch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 17, 2024
Brief Report: Low-Dose Methotrexate Does Not Affect Measures of HIV-1 Persistence in Individuals With Chronically Treated HIV-1 InfectionJoshua C Cyktor, Eunice Yeh, Heather Ribaudo, et al.
The Journal of Infectious Diseases|May 10, 2022
Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic SubstudyMárton Kolossváry, Chris deFilippi, Michael T Lu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 12, 2022
Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIVEdgar T Overton, Isabelle R Weir, Markella V Zanni, et al.
Journal of the American Heart Association|December 11, 2025
Baseline ECG and Cardiovascular Outcomes in People With HIV: Insights From REPRIEVEAya Awwad, Christopher de Filippi, Heather Ribaudo, et al.
AIDS (London, England)|May 27, 2025
Risks for sudden cardiac and undetermined cause of death among people with HIV in the REPRIEVE primary cardiovascular prevention trialChristopher deFilippi, Aya Awwad, Gerald S Bloomfield, et al.
JAMA Network Open|June 29, 2021
Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular PreventionUdo Hoffmann, Michael T Lu, Borek Foldyna, et al.
American Heart Journal|April 1, 2019
Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkersUdo Hoffmann, Michael T Lu, Devvora Olalere, et al.
JACC. Advances|June 28, 2024
Coronary Plaque in People With HIV vs Non-HIV Asymptomatic Community and Symptomatic Higher-Risk PopulationsJulia Karady, Michael T Lu, Göran Bergström, et al.
JAMA Cardiology|February 21, 2024
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical TrialMichael T Lu, Heather Ribaudo, Borek Foldyna, et al.
Pageof 5